Why the study?
Current guidelines require serial troponin tests for non-STEMI chest pain in the ED, but combining HEAR and HEART scores to safely forgo or limit troponin testing had not been evaluated in clinical practice.
Does a diagnostic strategy based on HEAR and HEART scores safely rule out major adverse cardiac events in patients presenting to the ED with chest pain compared to current guidelines?
Does a diagnostic strategy based on HEAR and HEART scores safely rule out major adverse cardiac events in patients presenting to the ED with chest pain compared to current guidelines?
This study protocol outlines a stepped-wedge cluster-randomized trial to evaluate whether a HEAR/HEART score-based strategy can safely reduce troponin testing in ED patients with chest pain.
May allow forgoing or single troponin testing in low-risk ED chest pain; leaves open whether HEAR-T safely reduces missed events.
INTRODUCTION: Current guidelines for patients presenting to the emergency department (ED) with chest pain without ST-segment elevation myocardial infarction (STEMI) on ECG are based on serial troponin measurements. A clinical tool able to identify very low-risk patients who could forgo a troponin test and low-risk patients requiring only one troponin measurement would be of great interest. To do so, the HEAR and HEART score, standing for history, ECG, age, risk factors±troponin were prospectively assessed, but not combined and implemented in clinical practice. The objective of the eCARE study is to assess the impact of implementing a diagnostic strategy based on a HEAR score <2 or a HEART score <4 (HEAR-T strategy) to rule out non-STEMI without or with a single troponin measurement in patients presenting to the ED with chest pain without obvious diagnosis after physical examination and an ECG. METHODS AND ANALYSIS: Stepped-wedge cluster-randomised control trial in 10 EDs. Patients with non-traumatic chest pain and no formal diagnosis were included and followed for 30 days. In the interventional phase, the doctor will be asked not to perform a troponin test to look for an acute coronary if the HEAR score is <2 and not to perform an additional troponin test if the HEAR score is ≥2 and HEART score is <4. The main endpoint is the non-inferiority of the rates of major adverse cardiac events occurring between a patient's discharge and the 30-day follow-up against current recommended guidelines. ETHICS AND DISSEMINATION: The study was approved by an institutional review board for all participating centres. If successful, the eCARE study will cover a gap in the evidence, proving that it is safe and efficient to rule out the hypothesis of an acute myocardial infarction in some selected very low-risk patients or based on a single troponin measurement in some low-risk patients. TRIAL REGISTRATION NUMBER: NCT04157790.
No takes yet. Share an insight, caveat, or question.
Moumneh et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: